Onset Therapeutics Launches Hylatopic Emollient Foam

Onset Therapeutics has launched Hylatopic Emollient Foam, a non-steroidal prescription product. It is indicated to manage and relieve the burning, itching and pain experienced with various types of dermatoses, including atopic dermatitis, allergic contact dermatitis and radiation dermatitis.

The company also received FDA approval for Hylatopic Emollient Foam. It is formulated to rapidly hydrate the stratum corneum (the top layer of the skin) and provide a semi-permeable barrier that protects against irritants and excessive water loss through the epidermis.

Michael Heffernan, president of Onset Therapeutics, said: We are very excited to be able to offer Hylatopic to our physicians and patients. It is well known that skin barrier dysfunction is a fundamental problem in atopic dermatitis patients. Hylatopic’s 3-step approach to hydrate, protect and restore the natural skin barrier, combined with the aesthetic and safety elements which drive compliance, assists in helping our physicians achieve the best therapeutic outcomes.